ATSE:EVROF

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Market Cap

€15.0m

Last Updated

2021/06/17 22:44 UTC

Data Sources

Company Financials

Executive Summary

Evrofarma SA produces and sells dairy products in Greece. More Details


Snowflake Analysis

Proven track record and slightly overvalued.

Share Price & News

How has Evrofarma's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: EVROF is not significantly more volatile than the rest of Greek stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: EVROF's weekly volatility (6%) has been stable over the past year.


Market Performance


7 Day Return

0.5%

EVROF

-0.2%

GR Food

-1.1%

GR Market


1 Year Return

16.8%

EVROF

22.3%

GR Food

-28.9%

GR Market

Return vs Industry: EVROF underperformed the Greek Food industry which returned 22.3% over the past year.

Return vs Market: EVROF exceeded the Greek Market which returned -28.9% over the past year.


Shareholder returns

EVROFIndustryMarket
7 Day0.5%-0.2%-1.1%
30 Day-0.9%8.1%3.7%
90 Day31.3%10.1%-7.7%
1 Year16.8%16.8%29.7%22.3%-27.7%-28.9%
3 Year84.9%84.9%95.3%78.2%-49.5%-51.2%
5 Year511.1%511.1%203.1%46.0%-50.0%-52.0%

Long-Term Price Volatility Vs. Market

How volatile is Evrofarma's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Evrofarma undervalued compared to its fair value and its price relative to the market?

13.93x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: EVROF (€1.1) is trading above our estimate of fair value (€0.14)

Significantly Below Fair Value: EVROF is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: EVROF is good value based on its PE Ratio (13.9x) compared to the Greek Food industry average (17.7x).

PE vs Market: EVROF is good value based on its PE Ratio (13.9x) compared to the Greek market (19x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate EVROF's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: EVROF's PB Ratio (1.2x) is in line with the GR Food industry average.


Future Growth

How is Evrofarma forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

8.8%

Forecasted Food, Beverage & Tobacco industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Evrofarma has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Evrofarma performed over the past 5 years?

6.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: EVROF has a large one-off gain of €297.0K impacting its December 31 2020 financial results.

Growing Profit Margin: EVROF's current net profit margins (3.2%) are higher than last year (0.5%).


Past Earnings Growth Analysis

Earnings Trend: EVROF's earnings have grown by 6.6% per year over the past 5 years.

Accelerating Growth: EVROF's earnings growth over the past year (585.1%) exceeds its 5-year average (6.6% per year).

Earnings vs Industry: EVROF earnings growth over the past year (585.1%) exceeded the Food industry 4.1%.


Return on Equity

High ROE: EVROF's Return on Equity (8.3%) is considered low.


Financial Health

How is Evrofarma's financial position?


Financial Position Analysis

Short Term Liabilities: EVROF's short term assets (€18.8M) exceed its short term liabilities (€10.7M).

Long Term Liabilities: EVROF's short term assets (€18.8M) do not cover its long term liabilities (€22.7M).


Debt to Equity History and Analysis

Debt Level: EVROF's debt to equity ratio (163.6%) is considered high.

Reducing Debt: EVROF's debt to equity ratio has reduced from 226.2% to 163.6% over the past 5 years.

Debt Coverage: EVROF's debt is not well covered by operating cash flow (6.9%).

Interest Coverage: EVROF's interest payments on its debt are not well covered by EBIT (1.8x coverage).


Balance Sheet


Dividend

What is Evrofarma current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate EVROF's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate EVROF's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if EVROF's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if EVROF's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of EVROF's dividend in 3 years as they are not forecast to pay a notable one for the Greek market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?


CEO

Paschalis Papazilakis (63 yo)

no data

Tenure

Mr. Paschalis H. Papazilakis is the Founder of Evrofarma S.A. and serves as its Vice Chairman and Chief Executive Officer.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Evrofarma SA's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Evrofarma SA
  • Ticker: EVROF
  • Exchange: ATSE
  • Founded: 1991
  • Industry: Packaged Foods and Meats
  • Sector: Food, Beverage & Tobacco
  • Market Cap: €15.041m
  • Shares outstanding: 13.67m
  • Website: https://www.evrofarma.gr

Number of Employees


Location

  • Evrofarma SA
  • 10 km Didimoticho - Orestiada
  • Didymoteicho
  • 68300
  • Greece

Listings


Biography

Evrofarma SA produces and sells dairy products in Greece. It offers milk and liquids, ayran, cheese and organic cheese, and yogurt. The company also exports its products to 13 countries. Evrofarma SA was f...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/06/17 22:44
End of Day Share Price2021/06/17 00:00
Earnings2020/12/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.